concept

PD-L1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PD-L1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

380Connections

0Hypotheses

1Analyses

50Outgoing

50Incoming

0Experiments

2Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	PD-L1
Key Genes/Proteins	Akt, APOB, APOPTOSIS, App, ARG1, ATM
Related Diseases	Aging, Als, ALS
Related Pathways	Apoptosis, autophagy, Autophagy

Wiki Pages (1)

Knowledge base pages for this entity

PD-1/PD-L1 Immune Checkpoint Signaling in Neurodegeneration

mechanism · 3120 words

→

Pathway Diagram

graph TD
    PD_L1["PD-L1"]
    PD_L1 -->|"promotes"| IL_6["IL-6"]
    PD_L1 -->|"inhibits"| T_Cell_Activity["T Cell Activity"]
    PD_L1 -->|"activates"| Jak2_Stat3_signaling["Jak2/Stat3 signaling"]
    PD_L1 -->|"binds"| PD_1["PD-1"]
    PD_L1 -->|"inhibits"| T_cells["T cells"]
    PD_L1 -->|"promotes"| oral_squamous_cell_carcinoma["oral squamous cell carcinoma"]
    PD_L1 -->|"inhibits"| PTPN1["PTPN1"]
    PD_L1 -->|"inhibits"| T_cell_function["T-cell function"]
    PER2["PER2"] -->|"inhibits"| PD_L1
    PINK1["PINK1"] -->|"recruits_to_mitochondria"| PD_L1
    OMA1["OMA1"] -->|"upregulates"| PD_L1
    PD_1 -->|"inhibits"| PD_L1
    TCe6_Cu_TP5_NPs["TCe6@Cu/TP5 NPs"] -->|"downregulates"| PD_L1
    NF__B["NF-kappaB"] -->|"activates"| PD_L1
    SMARCAL1["SMARCAL1"] -->|"promotes"| PD_L1
    Atezolizumab["Atezolizumab"] -->|"targets"| PD_L1

Outgoing (223)

Target	Relation	Type	Str
IL-6	promotes	protein	0.95
T Cell Activity	inhibits	process	0.95
Jak2/Stat3 signaling	activates	pathway	0.93
oral squamous cell carcinoma	promotes	disease	0.90
PTPN1	inhibits	protein	0.90
Immunotherapy	regulates	process	0.90
T cells	inhibits	cell_type	0.90
T-cell function	inhibits	process	0.90
STAT3	binds_to	protein	0.89
T Cell Cytotoxicity	inhibits	process	0.85
Cancer Cell Proliferation	involved_in	process	0.85
Systemic Immune Suppression	mediates	process	0.80
Cancer	inhibits	disease	0.65
ALS	inhibits	disease	0.65
Tumor	expressed_in	disease	0.65
ALS	expressed_in	disease	0.65
Carcinoma	biomarker_for	disease	0.65
Carcinoma	inhibits	disease	0.65
Tumor	degrades	disease	0.65
Cancer	degrades	disease	0.65
Glioblastoma	therapeutic_target	disease	0.65
Tumor	activates	disease	0.65
Cancer	activates	disease	0.65
Carcinoma	activates	disease	0.65
Als	expressed_in	disease	0.65
Cancer	biomarker_for	disease	0.65
Glioblastoma	activates	disease	0.65
Glioblastoma	inhibits	disease	0.65
ALS	activates	disease	0.65
Multiple Sclerosis	expressed_in	disease	0.65
Inflammation	activates	disease	0.65
Aging	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Cancer	associated_with	disease	0.65
Tumor	inhibits	disease	0.65
Lipid Metabolism	activates	pathway	0.60
Cholesterol	activates	pathway	0.60
Epithelial	activates	cell_type	0.60
Ubiquitin	therapeutic_target	protein	0.60
Immune Response	inhibits	pathway	0.60
FASN	activates	gene	0.60
Fus	activates	protein	0.60
App	therapeutic_target	protein	0.60
Raf	therapeutic_target	protein	0.60
Igf	therapeutic_target	protein	0.60
Ras	therapeutic_target	protein	0.60
ROS	inhibits	gene	0.60
VPS4A	inhibits	gene	0.60

Incoming (157)

Source	Relation	Type	Str
PER2	inhibits	gene	0.95
PD-1	inhibits	gene	0.95
PINK1	recruits_to_mitochondria	protein	0.95
OMA1	upregulates	protein	0.95
NAD+ depletion	upregulates	mechanism	0.95
Durvalumab	targets	drug	0.90
Avelumab	targets	drug	0.90
SMARCAL1	promotes	gene	0.90
Atezolizumab	targets	drug	0.90
STING1	associated_with	protein	0.90
type I interferon	associated_with	protein	0.90
cGAS-STING Pathway	upregulates	pathway	0.90
TCe6@Cu/TP5 NPs	downregulates	compound	0.90
NF-κB	activates	pathway	0.90
NUPR1	upregulates	gene	0.85
autophagy	mediates	pathway	0.85
JUN	interacts_with	protein	0.85
brain metastases	associated_with	disease	0.70
PD-1	activates	gene	0.65
IFN	associated_with	gene	0.60
SQSTM1	inhibits	gene	0.60
MCL1	therapeutic_target	gene	0.60
MDM4	therapeutic_target	gene	0.60
LZTR1	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
WNT	therapeutic_target	gene	0.60
DNA	therapeutic_target	gene	0.60
IGF2R	therapeutic_target	gene	0.60
GBM	therapeutic_target	gene	0.60
ROS	therapeutic_target	gene	0.60
DES	biomarker_for	gene	0.60
DNA	biomarker_for	gene	0.60
IBA1	expressed_in	gene	0.60
GBM	inhibits	gene	0.60
TMEM119	expressed_in	gene	0.60
HSPA9	associated_with	gene	0.60
CD68	expressed_in	gene	0.60
CMTM6	inhibits	gene	0.60
GLIOBLASTOMA	activates	gene	0.60
CCL2	inhibits	gene	0.60
GBM	activates	gene	0.60
LYSOSOME	inhibits	gene	0.60
DNA	activates	gene	0.60
HER2	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
CGAS-STING	therapeutic_target	gene	0.60
CGAS-STING	activates	gene	0.60
IFN	activates	gene	0.60
OMA1	interacts_with	gene	0.60
MITOPHAGY	activates	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimm

neuroinflammation | 2026-04-13 | 2 hypotheses Top: 0.738

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

The title suggests B cells actively maintain tolerance to AQP4, but the specific

closed · Rounds: 4 · Score: 0.66 · 2026-04-13

The title suggests B cells actively maintain tolerance to AQP4, but the specific

closed · Rounds: 4 · Score: 0.79 · 2026-04-13

Related Research

Hypotheses and analyses mentioning PD-L1 in their description or question text

No additional research found